Abstracts

358 – Chimeric Virus-Host Transcripts Reveal Integration Sites in Macaque SIV+ CD4 T Cells

Background Elucidating mechanisms governing proviral integration and transcription may aid in identifying strategies to limit HIV-1 reservoirs.  Chimeric host-viral transcripts are a mechanism by which HIV-1 modulates host gene expression to promote reservoir persistence, though they are poor characterized in vivo.  We analyzed SIV RNA+ CD4 T cells for viral, host, and chimeric transcripts during…

1095 – Hair and Point-of-Care Tenofovir Urine Self-Collection Feasible With Urine TFV Predicting Viral Load

Background Resurgent stimulant use among men who have sex with men (MSM) with HIV contributes to antiretroviral therapy (ART) adherence challenges. Objective monitoring of ART adherence and stimulant use via drug-level testing can inform interventions, surveillance, and future research. We developed a rapid, low-cost urine point-of-care (POC) tenofovir (TFV) assay as an objective adherence metric.…

661 – Multiomics Analysis of Oral Microbiome and Atherosclerosis in Women and Men With HIV

Background Although alterations in gut microbiota have been implicated in both HIV and atherosclerotic cardiovascular disease, the role of the oral microbiota remains less understood, particularly its potential connections to host immunity and inflammation in the context of HIV. Methods We examined associations of oral microbial features measured by 16S rRNA sequencing with carotid artery plaque(focal intima-media thickness >1.5 mm) assessed by B-mode ultrasound in…

392 – Genetic Diversification and Tissue-Resident Reservoir Persistence During ART Suppression

Background Antiretroviral therapy (ART) use has been instrumental in controlling disease progression in people living with HIV-1. However, pervasive, replication competent viral reservoirs, established during the early stages of infection, rapidly initiate viral rebound following treatment interruption. Although long-lived, circulating memory T cells have traditionally been considered the primary HIV reservoir; emerging data suggest that…

436 – bNAb-Secreting Hybrid CAR-T Cells Show HIV-Specific Activation In Vitro and Tissue Viral Suppression

Background Chimeric antigen receptor (CAR) T cell therapy represents a promising strategy for achieving HIV remission. We previously described Hybrid CAR-T cells engineered to secrete broadly neutralizing antibodies (bNAbs), which mediate both direct killing and Fc-dependent functions. Here, we present extended validation across additional donors, antigen-specific activation, resistance to infection and new in vivo studies relevant…

976 – Vending Machines as Stigma-Free Access Points for HIV/Syphilis Testing and Condoms

Background Memphis ranks second in the U.S. for new HIV diagnoses, underscoring an urgent need for innovative prevention. Testing remains heavily stigmatized, particularly among marginalized groups, limiting early diagnosis and care. Traditional clinic-based models often miss those who fear judgment or disclosure. To address this, we launched a free vending machine program in Memphis, distributing…

997 – Ultra-Long-Acting MPT Implant With Dolutegravir and Levonorgestrel for HIV PrEP and Contraception

Background HIV and unintended pregnancy remain intersecting global burdens on women’s health. Adherence challenges limit the effectiveness of oral HIV PrEP and contraception. We propose to develop an ultra-long-acting (ULA) in-situ forming implant (ISFI) multipurpose prevention technology (MPT) co-formulating dolutegravir (DTG) and levonorgestrel (LNG) as a once-yearly injectable to reduce dosing burden and enhance compliance.…

426 – Improved Antibody Function After env-mRNA Vaccination During cART Does Not Control SHIV Post-ATI

Background Autologous neutralizing antibodies (aNAbs) can possibly delay viral rebound by targeting the HIV reservoir upon viral reactivation. We evaluated the immunogenicity of a mRNA-based therapeutic vaccine to boost aNAbs functionality and delay viral rebound after treatment interruption (ATI). Methods Fifteen rhesus macaques (RMs) were infected with a barcoded SHIV CH505.TF and treated with cART…